4 Result(s)
within
Kageaki Taima
Oncology
-
Article
Open AccessReal-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
Afatinib, a second-generation epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC), was approved in Japan in 2014. This study evaluated clinical...
-
Article
Open AccessA phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
This phase I trial was conducted to determine the maximum tolerated dose (MTD) and recommended dose of afatinib for phase II trial in elderly patients with advanced non-small cell lung cancer (NSCLC) harboring...
-
Article
Open AccessA single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
We aimed to evaluate the efficacy and safety of nab-paclitaxel in patients with refractory advanced non-small cell lung cancer who failed previous chemotherapy.
-
Article
Open AccessA case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion gene
Lung cancer is the leading cause of cancer-related death worldwide. Epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitor (TKI) is used for the patients with EGFR-mutant lung cancer. Recently, phase...
